Clinicoepidemiological Profile of Severe Cutaneous Adverse Drug Reaction: A Retrospective Study

Damayanti Damayanti, Menul Ayu Umborowati, Sylvia Anggraeni, Cita Rosita Sigit Prakoeswa, Marsudi Hutomo, Hari Sukanto

= http://dx.doi.org/10.20473/bikkk.V31.1.2019.1-6
Abstract views = 163 times | views = 98 times

Abstract


Background: Drug eruption were varied from mild to severe reaction. Few studies have assessed the severe cutaneous adverse drug reaction (SCADR), especially in the setting of general hospital. Purpose: To evaluate clinicoepidemiological profile of SCADR at Dermatology and Venereology Ward Dr. Soetomo Hospital, Surabaya, Indonesia. Methods: All SCADR patients at Dr. Soetomo Hospital, Surabaya, Indonesia in the period of January 2016 – June 2017 was evaluated. Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and exfoliative dermatitis cases were included in the study. Results: There were 24 patients in this study, consisted of 11 SJS cases, 1 TEN case, 2 SJS/TEN-overlap cases, 10 exfoliative dermatitis cases. The mean of latent period between drug intake and onset of symptoms was 15.8 days. The most common offending drug was mefenamic acid (20.9%), followed by cefadroxil and phenytoin (each 16.7%). Antibiotics was the highest frequent offending drug-groups (62.5%), followed by non-steroid anti-inflammatory drugs (NSAIDs). Prompt withdrawal of the offending drugs, systemic corticosteroid, and supported therapy were given to all patients, which gave good results in 21/24 patients (87.5%). Conclusion: Antibiotics were the most common offending drug-groups. SCADR might give high mortality rate, but early diagnosis, prompt withdrawal of the suspected drugs, closed monitoring to evaluate complications can improve the prognosis of SCADR.


Keywords


clinicoepidemiology; severe CADR;

Full Text:

PDF

References


Grando LR, Schhmitt TA, Bakos RM. Severe cutaneous reactions to drugs in the setting of a general hospital. An Brass Dermatol 2014; 89(5): 758-62.

Shear NH, Knowles SR. Cutaneous reactions to drugs. In: Goldsmith AI, Katz S, Gilchrest A, Paller A, Leffel D, Wolff K,eds. Fitzpatrick Dermatology in General Medicine. 8thed. New York: McGraw Hill; 2012. P. 449-57.

Verma CR, Vasudevan LCB, Pragasam LCV. Severe cutaneous adverse drug reactions. Medical Journal Armed Forces India 2013; 69: 375-83.

Sasidharanpillai S, Riyaz N, Khader A, Rajan U, Binitha MP, Sureshan DN. Indian J Dermatol 2015; 60(1): 102.

Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011; 71 (5): 684-700.

Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. IJVDL 2012; 78(6): 734-9.

Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol 2008; 53(1): 2-8.

Borges MS, Foncesa FC, Hullet AC, Aveledo LG. Hypersensitivity reaction to NSAID: an up date. Pharmaceuticals 2010; 3: 10-8.

Harr T, Rench LE. Toxic epidermal necrolysis and Stvens-Johnson syndrome. Orphanet Journal of Rare Disease 2010; 5: 39-46.

Ho HHF. Diagnosis and Management of Stevens-Johnson suyndrome and toxic epidermal necrolysis. Hong Kong Medical Diary 2008; 13(10): 17-20.

Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010; 11(7):973-87.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Berkala Ilmu Kesehatan Kulit dan Kelamin

 

 

Lisensi Creative Commons
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial 4.0 Internasional.

View My Stats